Login / Signup
Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly.
Steven Mark Sorscher
Published in:
Journal of breast cancer (2022)
Keyphrases
</>
epidermal growth factor receptor
advanced non small cell lung cancer
metastatic breast cancer
early stage
tyrosine kinase
drug induced